Breaking News

FDA rejects Pfizer's long-acting growth hormone

Not rendering correctly? View this email as a web page here.

Virtual physical therapy offered in-network to select Medicare Advantage customers

By Emma Bardin Monday, January 24, 2022 7:58 AM

RecoveryOne will now offer their virtual physical therapy app for musculoskeletal (MSK) injuries as an in-network benefit to some Cigna Medicare Advantage Customers.

Read more »

How payment integrity tools can help payers to tackle fraud, waste and abuse

By Subrahmanyam Mantha Monday, January 24, 2022 12:59 AM

Although telehealth offers many benefits for patients, it introduces operational complexities for providers and creates legitimate concerns about fraud, waste and abuse for payers.

Read more »

AI revolutionizes hospital procurement services

By Ashley Mehta Monday, January 24, 2022 12:50 AM

AI can process hundreds of thousands of products or contracts in one business day or less—an achievement that would take years if it was a manual task.

Read more »

Pfizer's growth hormone deficiency drug comes up short at the FDA

By Frank Vinluan Sunday, January 23, 2022 8:01 AM

The FDA has rejected Pfizer's somatrogon, a long-acting form of human growth hormone designed for once-weekly dosing. The setback delays Pfizer and partner Opko Health from competing against a newly approved human growth hormone drug from Ascendis Health that is also designed for once-weekly dosing.

Read more »

   

No comments